Dynavax Technologies Corporation (DVAX) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $15.50
• Market Cap: $1.82B
• EPS: $-0.37
• 52-Week High: $15.73
• 52-Week Low: $9.20

Market Sentiment

Dynavax Technologies Corporation currently has a Neutral sentiment score of -0.01.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation (DVAX) is a biopharmaceutical firm based in Emeryville, California, focused on the development and commercialization of innovative vaccines aimed at addressing major public health challenges. The company is recognized for its proprietary immunotherapy platform which enhances vaccine efficacy, exemplified by its lead product, HEPLISAV-B, a hepatitis B vaccine approved in the U.S. and various international markets. With a promising pipeline and strong strategic ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Dynavax Technologies Corporation and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does DVAX pay dividends?

Dynavax Technologies Corporation (DVAX) does not currently pay a regular dividend.

What is DVAX's market cap?

Dynavax Technologies Corporation (DVAX) has a market capitalization of $1.82B with a current stock price of $15.50.